Cargando…
Ruxolitinib Reduces Oxidative Stress in Patients With Primary Myelofibrosis: A Multicenter Study
Introduction Primary myelofibrosis (PM) has a lower overall survival rate than other myeloproliferative neoplasms, and leukemic transformation is the most common cause of death. Increased oxidative stress has an important role in leukemic transformation in these patients. In this study, we aimed to...
Autores principales: | Koyuncu, Mahmut B, Ilgan, Mustafa, Basir, Hakan, Tombak, Anil, Ucar, Mehmet Ali, Koseci, Tolga, Akdeniz, Aydan, Tiftik, Eyup N, Erel, Özcan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812273/ https://www.ncbi.nlm.nih.gov/pubmed/35145818 http://dx.doi.org/10.7759/cureus.20929 |
Ejemplares similares
-
Cardiac Chamber Quantification by Echocardiography in Adults With Sickle Cell Disease: Need Attention to Eccentric Hypertrophy
por: Koyuncu, Mahmut B, et al.
Publicado: (2021) -
Is dynamic thiol/disulfide homeostasis associated with the prognosis of myelodysplastic syndrome?
por: Ali, Ucar Mehmet, et al.
Publicado: (2020) -
Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013) -
Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib
por: Shanthosh Kumar, Sandhya, et al.
Publicado: (2021) -
Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
por: SOYER, Nur, et al.
Publicado: (2021)